130.93 USD
+7.11 (+5.74%)
130.9 USD
-0.03 (-0.02%)
Overall TMDX gets a fundamental rating of 6 out of 10. We evaluated TMDX against 188 industry peers in the Health Care Equipment & Supplies industry. TMDX has an average financial health and profitability rating. TMDX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes TMDX very considerable for growth investing!
1. Profitability
1.1 Basic Checks
TMDX had positive earnings in the past year.
TMDX had a positive operating cash flow in the past year.
In the past 5 years TMDX reported 4 times negative net income.
In the past 5 years TMDX reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of TMDX (9.71%) is better than 92.55% of its industry peers.
With an excellent Return On Equity value of 25.88%, TMDX belongs to the best of the industry, outperforming 96.28% of the companies in the same industry.
With an excellent Return On Invested Capital value of 8.72%, TMDX belongs to the best of the industry, outperforming 87.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.71% | ||
| ROE | 25.88% | ||
| ROIC | 8.72% |
ROA(3y)-4.09%
ROA(5y)-12.79%
ROE(3y)-7.43%
ROE(5y)-23.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TMDX has a better Profit Margin (16.22%) than 92.55% of its industry peers.
With an excellent Operating Margin value of 16.89%, TMDX belongs to the best of the industry, outperforming 87.23% of the companies in the same industry.
TMDX has a Gross Margin of 60.28%. This is comparable to the rest of the industry: TMDX outperforms 59.57% of its industry peers.
In the last couple of years the Gross Margin of TMDX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.89% | ||
| PM (TTM) | 16.22% | ||
| GM | 60.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), TMDX is creating some value.
The number of shares outstanding for TMDX has been increased compared to 1 year ago.
TMDX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TMDX has been reduced compared to a year ago.
2.2 Solvency
TMDX has an Altman-Z score of 5.58. This indicates that TMDX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of TMDX (5.58) is better than 78.72% of its industry peers.
TMDX has a debt to FCF ratio of 4.27. This is a neutral value as TMDX would need 4.27 years to pay back of all of its debts.
The Debt to FCF ratio of TMDX (4.27) is better than 79.79% of its industry peers.
TMDX has a Debt/Equity ratio of 1.43. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of TMDX (1.43) is worse than 79.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.27 | ||
| Altman-Z | 5.58 |
ROIC/WACC1.09
WACC7.99%
2.3 Liquidity
TMDX has a Current Ratio of 7.66. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 7.66, TMDX belongs to the best of the industry, outperforming 89.36% of the companies in the same industry.
A Quick Ratio of 7.10 indicates that TMDX has no problem at all paying its short term obligations.
TMDX's Quick ratio of 7.10 is amongst the best of the industry. TMDX outperforms 89.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.66 | ||
| Quick Ratio | 7.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 162.77% over the past year.
The Revenue has grown by 41.20% in the past year. This is a very strong growth!
TMDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 79.64% yearly.
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
3.2 Future
TMDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.52% yearly.
TMDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.23% yearly.
EPS Next Y162.03%
EPS Next 2Y69.97%
EPS Next 3Y53.74%
EPS Next 5Y44.52%
Revenue Next Year39.7%
Revenue Next 2Y29.73%
Revenue Next 3Y25.57%
Revenue Next 5Y21.23%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 53.01 indicates a quite expensive valuation of TMDX.
Compared to the rest of the industry, the Price/Earnings ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 68.62% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of TMDX to the average of the S&P500 Index (25.47), we can say TMDX is valued expensively.
With a Price/Forward Earnings ratio of 44.87, TMDX can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, TMDX is valued a bit cheaper than the industry average as 69.68% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.42, TMDX is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 53.01 | ||
| Fwd PE | 44.87 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, TMDX is valued a bit cheaper than the industry average as 69.15% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, TMDX is valued a bit cheaper than the industry average as 76.06% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 37.28 | ||
| EV/EBITDA | 37.16 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TMDX's earnings are expected to grow with 53.74% in the coming years.
PEG (NY)0.33
PEG (5Y)N/A
EPS Next 2Y69.97%
EPS Next 3Y53.74%
5. Dividend
5.1 Amount
No dividends for TMDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
130.93
+7.11 (+5.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners111.43%
Inst Owner Change1.45%
Ins Owners2.96%
Ins Owner Change-0.12%
Market Cap4.47B
Revenue(TTM)566.35M
Net Income(TTM)91.86M
Analysts83.16
Price Target146.29 (11.73%)
Short Float %22.8%
Short Ratio7.88
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.22%
Min EPS beat(2)84.39%
Max EPS beat(2)100.04%
EPS beat(4)4
Avg EPS beat(4)92.06%
Min EPS beat(4)16.42%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)202.42%
EPS beat(12)10
Avg EPS beat(12)118.6%
EPS beat(16)12
Avg EPS beat(16)90.24%
Revenue beat(2)1
Avg Revenue beat(2)0.71%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)4.34%
Revenue beat(4)3
Avg Revenue beat(4)5.83%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)7.35%
Revenue beat(12)10
Avg Revenue beat(12)12.14%
Revenue beat(16)14
Avg Revenue beat(16)18.13%
PT rev (1m)-2.1%
PT rev (3m)-5.02%
EPS NQ rev (1m)1.89%
EPS NQ rev (3m)3.41%
EPS NY rev (1m)9.81%
EPS NY rev (3m)10%
Revenue NQ rev (1m)0.45%
Revenue NQ rev (3m)0.44%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)-0.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 53.01 | ||
| Fwd PE | 44.87 | ||
| P/S | 7.9 | ||
| P/FCF | 37.28 | ||
| P/OCF | 25.13 | ||
| P/B | 12.6 | ||
| P/tB | 13.12 | ||
| EV/EBITDA | 37.16 |
EPS(TTM)2.47
EY1.89%
EPS(NY)2.92
Fwd EY2.23%
FCF(TTM)3.51
FCFY2.68%
OCF(TTM)5.21
OCFY3.98%
SpS16.57
BVpS10.39
TBVpS9.98
PEG (NY)0.33
PEG (5Y)N/A
Graham Number24.03
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.71% | ||
| ROE | 25.88% | ||
| ROCE | 11.04% | ||
| ROIC | 8.72% | ||
| ROICexc | 18.9% | ||
| ROICexgc | 19.58% | ||
| OM | 16.89% | ||
| PM (TTM) | 16.22% | ||
| GM | 60.28% | ||
| FCFM | 21.19% |
ROA(3y)-4.09%
ROA(5y)-12.79%
ROE(3y)-7.43%
ROE(5y)-23.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.27 | ||
| Debt/EBITDA | 4.17 | ||
| Cap/Depr | 223.08% | ||
| Cap/Sales | 10.24% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 146.33% | ||
| Profit Quality | 130.63% | ||
| Current Ratio | 7.66 | ||
| Quick Ratio | 7.1 | ||
| Altman-Z | 5.58 |
F-Score7
WACC7.99%
ROIC/WACC1.09
Cap/Depr(3y)950.14%
Cap/Depr(5y)614.59%
Cap/Sales(3y)35.03%
Cap/Sales(5y)23.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
EPS Next Y162.03%
EPS Next 2Y69.97%
EPS Next 3Y53.74%
EPS Next 5Y44.52%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
Revenue Next Year39.7%
Revenue Next 2Y29.73%
Revenue Next 3Y25.57%
Revenue Next 5Y21.23%
EBIT growth 1Y204.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year292.7%
EBIT Next 3Y89.1%
EBIT Next 5Y68.49%
FCF growth 1Y186.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y801.62%
OCF growth 3YN/A
OCF growth 5YN/A
TRANSMEDICS GROUP INC / TMDX FAQ
Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to TMDX.
What is the valuation status for TMDX stock?
ChartMill assigns a valuation rating of 5 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.
How profitable is TRANSMEDICS GROUP INC (TMDX) stock?
TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for TMDX stock?
The Price/Earnings (PE) ratio for TRANSMEDICS GROUP INC (TMDX) is 53.01 and the Price/Book (PB) ratio is 12.6.
What is the financial health of TRANSMEDICS GROUP INC (TMDX) stock?
The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 6 / 10.